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ABSTRACT 
Epithelial-mesenchymal transition (EMT) is a developmental process defined by loss 
of epithelial characteristics and acquisition of mesenchymal phenotype. EMT or 
similar processes are also implicated in carcinoma cell invasion and the progression 
of breast carcinoma to metastasis. In a cell model system for mammary 
carcinogenesis it has previously been shown that signaling from the oncogenic 
receptor tyrosine kinase c-erbB2 (HER2), frequently overexpressed in mammary 
cancers, induces EMT. In this system, c-erbB2-induced EMT was significantly 
delayed by high cell-density and cell-cell-dissociation occurred before 
downregulation of the epithelial adhesion molecule E-cadherin. Loss of E-cadherin 
expression is generally viewed as a fundamental event in EMT. This thesis shows 
that ectopic expression of E-cadherin concomitant with c-erbB2 signaling did not 
hinder the progression of EMT. E-cadherin expressed in mesenchymal cells had a 
weaker attachment to the cytoskeleton, implicating that rearrangement of the 
cytoskeleton is an important mechanism in EMT-associated cell-cell-dissociation. 
Expression of dominant negative E-cadherin weakened cell-cell adhesion but did not 
enable EMT at high cell-density. These finding indicate that loss of E-cadherin is a 
consequence rather than a cause of EMT and that density-dependent inhibition of 
EMT is not mediated by E-cadherin. The expression of the transcription factor 
nuclear factor I-C2 (NFI-C2) is lost during mammary tumor progression and NFI-C2 
has been shown to counteract EMT by repressing the transcription factor Forkhead 
box F1 (FoxF1). FoxF1 induces EMT and invasiveness in breast cancer cells. In this 
thesis, Affymetrix microarray was used to find oppositely regulated targets of NFI-
C2 and FoxF1. The extracellular matrix enzyme lysyl oxidase (LOX) was found to 
be negatively regulated by NFI-C2 and positively regulated by FoxF1 and 
responsible for the increased invasiveness caused by FoxF1 overexpression. A 
signaling pathway was identified where FoxF1-induced upregulation of LOX 
activated focal adhesion kinase, subsequently suppressing Smad2 activity. In parallel, 
overexpression of FoxF1 activated the p38 MAPK signaling pathway. These findings 
give new insights into the regulation of signaling pathways known to be important 
during breast tumor progression. Based on the findings that NFI-C2 is lost during 
breast tumor progression and suppresses EMT, the prognostic value of NFI-C2 in a 
mixed cohort of breast cancer patients was investigated. NFI-C2 was found to be a 
powerful prognostic marker associated with good prognosis in breast cancer. 
Keywords: breast cancer, epithelial-mesenchymal transition, c-erbB2, E-cadherin, 
NFI-C2, FoxF1, LOX 
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INTRODUCTION 
Mammary gland 
The mammary gland is a secretory organ, producing milk. It consists of a 
ductal network surrounded by a stroma compartment. Mammary ducts are 
formed by two main types of epithelial cells; luminal and basal. The luminal 
cells forms the ducts and alveoli and have secretory properties. The basal 
epithelium consists of contractile myoepithelial cells that surround the 
luminal epithelium. A basement membrane is lining the basal epithelium. The 
stroma compartment contains extracellular matrix (ECM), stromal cells, 
immune cells and adipocytes, making up the fat pad (Fig. 1) [1, 2]. 
 
 
Figure 1. Schematic picture of the mammary gland 
The development of the human breast is a progressive process proceeding in 
distinct phases; embryonic development, pre-pubertal growth, pubertal 
expansion, pregnancy- and lactation-associated remodeling, and post-
lactational and post-menopausal involution [3]. The mammary gland reaches 
its full mature state during the pregnancy-lactation cycle. During the distinct 
phases of mammary gland development there is progressive ductal elongation 
and branching followed terminal differentiation at parturition and involution 
characterized by apoptosis and tissue remodeling during weaning [4, 5]. 
The development and function of the mammary gland are influenced by a 
number of growth factors and hormones, e.g. estrogen, progesterone, 
prolactin and epidermal growth factor [6, 7], and also dependent on 
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interactions between stromal and epithelial cells. Signals from stromal cells, 
as well as the composition of the ECM (laminin, fibronectin, collagen, 
proteoglycans etc.) help epithelial cells to generate and maintain apico-basal 
polarity [8]. In response to extracellular signals, integrins (transmembrane 
receptors for ECM) activate growth and survival signals [9]. Moreover, many 
of the factors important for mammary gland development are also implicated 
in breast cancer. During the development of the mammary gland the 
epithelium shows high levels of proliferation, reduced apico-basal polarity 
and epithelial-mesenchymal plasticity, characteristics also associated with 
tumorigenesis [10]. 
Breast cancer 
Breast cancer development is a multi-step process categorized by different 
stages [11]. These stages include cellular immortality, hyperplasia, 
tumorigenicity and invasiveness. During these stages there is an initial 
epithelial hyperplasia, which can develop into atypical hyperplasia, in situ 
carcinoma, invasive carcinoma and metastasis. Breast cancer can begin in 
different areas of the mammary epithelium; the ducts or the lobules and most 
commonly derived from the luminal cells [12]. It is a heterogeneous disease 
with different subtypes. These subtypes show differences in the molecular 
profile, response to therapy and prognosis. The molecular subtypes are; 
luminal A, luminal B, molecular apocrine, basal-like, HER2, normal breast-
like and claudin-low [13-15].  
The mechanisms important for normal breast function are also important in 
suppressing the development of tumors by regulating proliferation and 
survival. Genetic and epigenetic changes leading to dysregulation of these 
normal processes can cause uncontrolled proliferation and imbalance 
between proliferation and apoptosis, promoting carcinogenesis. Inherited or 
acquired mutations in oncogenes (e.g. HER2, MYC, CCND1, PIK3CA [16-
19]) and tumor suppressors (e.g. P53, BRCA1/2, RB1, PTEN [20-24]) are 
associated with breast cancer. Hormones and growth factors controlling 
normal mammary gland development together with their receptors and co-
regulators are also involved in the development of breast cancer. If these 
factors are dysregulated it can lead to amplification of growth and survival 
signals [25].  
In addition, microRNAs (miRNAs) have been shown to play key roles in 
carcinogenesis. miRNAs are small non-coding RNA molecules that control 
post-transcriptional gene expression by binding to target messenger RNAs, 
causing their degradation and downregulation of the target protein. Some 
function as tumor suppressors and others act as oncogenes [26-28]. 
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As a response to the genetic alterations in the epithelial cells, there are 
alterations in the microenvironment, such as increased levels of growth 
factors and cytokines, and increased matrix synthesis, cross-linking and ECM 
stiffening. Matrix stiffening increases integrin signaling, promoting cell 
growth, survival and tumor progression [29-32]. 
It has been suggested that different cell types or transformation of mammary 
stem cells at different developmental stages are the cause of the different 
breast cancer subtypes. The more aggressive breast cancer subtypes are 
suggested to originate from mammary stem cells and the less aggressive 
subtypes from more differentiated mammary cells [2, 33-35]. 
Cancer stem cells (CSCs) were first identified in hematopoietic cancers and 
later in solid tumors such as breast tumors [36-38]. The existence of CSCs in 
the breast was suggested in a study demonstrating that only a minority of 
cancer cells have the ability to form new tumors. Tumorigenic (cancer-
initiating) and non-tumorigenic cancer cells were identified based on 
differences in molecular markers [38]. Tumorigenic cancer cells have the 
ability to self-renew and produce progeny that are able to differentiate, which 
are properties of normal stem cells [39]. CSCs also have metastatic properties 
such as increased motility [40]. 
The invasion-metastasis cascade 
Metastases are formed by a multi-step process. Cancer cells that have 
acquired the ability to disseminate from the primary tumor can travel through 
the blood and lymphatic system to distant sites in the body where they can 
form new colonies (metastases). The process when carcinoma cells acquire 
the ability to break through the basement membrane and invade the nearby 
stroma is termed localized invasion. The step when cancer cells enter the 
blood and lymphatic vessels is called intravasation. The migrating cells may 
die from anoikis, a form of apoptosis triggered by detachment from the ECM. 
They can also survive for long periods and in some instances extravasate into 
the surrounding tissue, leading to formation of micrometastases. If the 
foreign tissue microenvironment is favorable, the cancer cells may begin to 
proliferate and form a secondary tumor, a process termed colonization (Fig. 
2) [41]. Carcinomas are benign as long as the tumor cells do not break 
through the basement membrane and malign when they have acquired the 
ability to metastasize which is the leading cause of death in cancer patients. 
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Figure 2.  Schematic picture of cancer cell invasion and metastasis. 1. Normal 
epithelium. 2. Carcinoma in situ, 3. Invasive carcinoma. 4. Intravasation. 5. 
Extravasation. 6. Micrometastasis. 7. Colonization. 
Epithelial-mesenchymal transition 
Epithelial and mesenchymal cell phenotypes are not always permanent. 
During development it is critical that cells can change in morphology and 
behavior for proper morphogenesis. They do this by converting between the 
epithelial and mesenchymal phenotypes. These processes are termed 
epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial 
transition (MET) [42]. EMT and MET are critical during developmental 
stages such as gastrulation [43], neural crest formation [44], and heart valve 
formation [45], as well as other morphogenetic events. EMT has also been 
observed during branching morphogenesis in the mammary gland [46]. 
EMT involves activation of genes that are critical for creating the 
mechanisms needed for cell migration through the ECM. Epithelial cells are 
attached to each other by different junctions (tight junctions, adherens 
junctions and desmosomes). During EMT, these junctions dissolve, allowing 
epithelial cells to separate, lose apical- basal polarity and gain motility. The 
epithelial cell-cell adhesion molecule E-cadherin, and epithelial-specific 
integrins, are replaced by mesenchymal specific N-cadherin and integrins 
specific for a more transient adhesion. The epithelial intermediate filaments, 
cytokeratins, are replaced by vimentin [47]. The underlying basement 
membrane is degraded by matrix metalloproteinases (MMPs) and the cell 
migrates into the surrounding stroma (Fig. 3). After migration to a distant 
site, the mesenchymal cells may return to a epithelial phenotype by 
undergoing MET [48]. 
Gisela Nilsson 
5 
 
Figure 3. Epithelial-mesenchymal transition. To migrate and to invade a cell needs 
to detach from the neighboring cells in the epithelium. E-cadherin and epithelial 
adhesion complexes are replaced by mesenchymal adhesion complexes. Epithelial 
cells lose their polarity and gain motility and a mesenchymal morphology. The 
cytoskeleton is remodeled and vimentin is expressed. There is an increase in 
expression and secretion of extracellular components, e.g. fibronectin. The figure is 
adapted from [49]. 
Besides being critical during development, EMT is involved during wound 
healing. Keratinocytes at the edge of a wound undergo EMT and MET during 
the wound healing process [50]. EMT or EMT-like events have also been 
implicated in fibrosis [51] and cancer metastasis [52]. There are similarities, 
but also differences, between EMT events during development and other 
processes, leading to the classification of three different EMT types. Type 1 
refers to developmental EMTs; type 2 includes EMT events in wound healing 
and fibrosis; and type 3 refers to the EMT associated with cancer metastasis. 
One difference between type 2 and 3 to type 1 is the existence of an 
inflammatory response, which does not exist in embryos [53]. 
Molecular players involved in EMT 
EMT is driven by a network of transcription factors including Snail1, Snail2 
(also known as Slug), and Snail3, Zeb1 and Zeb2, Twist1 and Twist2 and 
others. Their expression is triggered in response to extracellular signals 
derived from the cellular microenvironment. Potent inducers of EMT are 
members of the transforming growth factor–β (TGF-β) family [54, 55], 
epidermal growth factor (EGF) [56, 57], fibroblast growth factor (FGF) [58, 
59] and platelet-derived growth factor (PDGF), but also Wnt [60], Notch 
[61], Hedgehog [62] and nuclear factor-κB (NF-κB) [63]. Receptor tyrosin 
kinases (RTKs), as well as other types of receptors, and a wide range of 
signaling pathways transduce EMT initiating signals and several pathways 
work in cooperation in order to full transition to a mesenchymal phenotype. 
Activation of Ras and Src pathways are involved in dissociation of adherens 
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junctions and desmosomes and remodeling of cytoskeleton by regulating the 
Rho family of GTPases [64]. Hypoxia (oxygen deprivation in the 
microenvironment) can also drive EMT during development or tumor 
progression. The hypoxic response is mainly mediated by hypoxia inducible 
factor-1 (HIF-1) which can promote EMT by regulation of Twist [65]. 
miRNAs have also emerged as key players in EMT and MET. The miRNA-
200 family are proposed to be involved in reversible switching between 
epithelial and mesenchymal state [66].  
EMT in cancer 
In cancer, genetic and epigenetic events lead to alterations in cancer cell 
phenotype. These changes become most evident when cancer cells leave the 
epithelium and initiate metastasis (Fig. 2 and 3). Carcinoma cells at the 
invasive front of a tumor may lose epithelial traits and acquire a 
mesenchymal phenotype. Signals supplied by stromal cells, that secrete 
growth factors and cytokines, also contributes in the transition to 
mesenchymal phenotype [30, 67].  
Signaling pathways and downstream effectors involved in the phenotypic 
changes needed for a carcinoma cell to detach from the epithelium seems to 
be highly similar to the events that orchestrate developmental EMT. 
Therefore, EMT or EMT-like events have been implicated in tumor invasion 
and metastasis, especially in the early steps of metastasis by facilitating cell 
dissemination and thereby generation of circulating tumor cells (CTCs). The 
revers process, MET, is believed to be responsible for the formation of 
metastases at distant organs [68]. Constitutive expression of transcription 
factors associated with EMT, suppresses metastasis formation, suggesting 
that EMT transcription factors must be downregulated for metastases to form 
[69-71]. In addition, high expression of E-cadherin is seen in breast cancer 
metastases [72, 73], suggesting that re-expression of epithelial markers is 
necessary for formation of metastases.  
It is difficult to study EMT in human tumors, since EMT is considered a 
transient event and a tumor specimen represents only one instant. However, 
EMT in cultured cells and animal models has been intensely studied. 
Multiple signaling pathways and often cooperation of different pathways has 
been shown to be involved in the initiation and progression of EMT in cancer 
cell models. Overexpression of RTKs, e.g. EGF receptors, or constitutive 
signaling from Ras, can drive EMT by activating Raf/MAPK- and PI3K 
pathways leading to expression of transcription factors like Snail, Slug Twist 
and Zeb1 [74-76]. There are many studies implicating TGF-β as a master 
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regulator of EMT, and cooperation of TGF-β with Ras or RTKs has been 
shown to cause EMT [77].  
Expression of mesenchymal markers have been observed in breast 
carcinomas of the basal and triple-negative subtypes [78]. However, such 
tumors also contain epithelial markers, suggesting that they have undergone a 
partial EMT [79, 80].  
It has been proposed that EMT can generate CSCs [81], however the origin 
of CSCs is a subject of debate. It has been shown that in mammary epithelial 
cells, expression of Twist1 or Snail, or treatment with TGF-β increases the 
number of cells with CSCs properties (CD44
high
/CD24
low
) [82, 83]. EMT 
markers and stem cell markers are coexpressed in CTCs from breast cancer 
patients with metastasis [84, 85] . 
Important factors controlling EMT 
As described above there are many factors involved in EMT. The studies 
included in this thesis have focused specifically on four different factors that 
have been shown to be involved in breast tumor development and EMT. The 
following sections in the introduction will be about these factors. 
E-cadherin 
E-cadherin (E for epithelia), also known as cadherin-1 (CDH-1), uvomorulin 
and L-CAM, belongs to the type-1 classical cadherin family and is the major 
cell adhesion molecule (CAM) involved in binding between neighboring 
cells in adherens junctions. 
Cadherins play a central role during the development and maintenance of 
multicellular organisms. E-cadherin helps to provide mechanically strong 
adhesive links between cells in the tissue and is important in defining apico–
basal polarity and maintaining epithelial morphology. E-cadherin is 
expressed early in embryonic development and initiates polarization of cells 
to form the blastocyst [86]. E-cadherin knockout studies in mice show 
lethality at the blastocyst stage [87]. Conditional gene inactivation of E-
cadherin in the mouse mammary gland leads to altered epithelial 
differentiation and cell death [88]. 
The extracellular domain of E-cadherin consists of five repetitive domains. 
The outermost part of E-cadherin contains an adhesion recognition motif 
important for binding specificity to identical cadherin molecules [89]. E-
cadherin molecules form Ca
2+
 dependent complexes, also involving catenins; 
β-catenin/α-catenin or γ-catenin (plakoglobin)/α-catenin and p120 catenin, 
mediating linkage to the actin cytoskeleton (Fig. 4) [90-92]. β-catenin and γ-
catenin both interact with E-cadherin but since their binding sites overlap 
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they cannot bind simultaneously. α-catenin is an actin binding protein and is 
believed to link the catenin-cadherin complex to the cytoskeleton [93]. 
However, it has been demonstrated that α-catenin cannot bind actin and β-
catenin at the same time [94, 95], suggesting additional complexity. 
 
Figure 4. Schematic drawing of the organization of E-cadherin in adherens 
junctions. E-cadherin is a 120 kDa protein expressed on the surface of epithelial 
cells. E-cadherin contains five extracellular domains, a single transmembrane 
domain and a cytoplasmic domain which interacts with catenins connecting E-
cadherin to the cytoskeleton; β-catenin (β), γ-catenin (γ) and α-catenin (α). p120 
catenin binds to juxtamembrane domain of E-cadherin. E-cadherins exerts 
homophilic interactions between neighboring cells, forming a “zipper” structure. 
Regulation of adherens junction formation and stability involves both 
transcriptional and posttranscriptional regulation of E-cadherin. The levels of 
E-cadherin expression [96] and the levels of cytosolic β-catenin regulate the 
strength of adhesion [97]. The amount of E-cadherin available for adhesion 
can also be regulated by recycling of endocytosed E-cadherin [98] and 
proteolytic cleavage [99].  
E-cadherin expression is lost during the development of most epithelial 
cancers. Loss of E-cadherin expression is suggested to be one of the key steps 
in EMT, invasion and metastasis [100]. Consequently, E-cadherin is referred 
to as a tumor suppressor and forced re-expression of E-cadherin in carcinoma 
cells can reverse malignant properties [101]. Loss of E-cadherin expression is 
a typical feature of invasive lobular carcinoma [102]. However, other types of 
breast cancer show variable downregulation of E-cadherin expression [103, 
104]. 
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c-erbB2 
The c-erbB family of RTKs, includes epidermal growth factor receptor 
(EGFR; c-erbB1, HER1), c-erbB2 (Neu, HER2), c-erbB3 (HER3) and c-
erbB4 (HER4), which are activated by a number of ligands, e.g. EGF, TGF-α 
and heregulin. c-erbB receptors consist of an extracellular ligand binding 
domain, a single transmembrane domain and an intracellular kinase and 
substrate domain. Upon ligand binding they form a variety of homo- or 
heterodimers leading to activation and phosphorylation [105]. Activation of 
these receptors induces cell growth, proliferation, differentiation and survival 
signals, including Rho GTPases, the Ras-MAP kinase cascade, PI3K and 
phospholipase Cγ [106]. c-erbB2 and c-erbB3 activity require 
heterodimerization with other c-erbBs since c-erbB2 does not bind growth 
factor ligands, and c-erbB3 lacks intrinsic kinase activity [107]. The c-erbB 
family plays crucial roles in heart and nervous system development [108-
111] and epithelial morphogenesis, for example in the development of 
embryonic and adult mammary gland [112-114]. 
c-erbB2 is a glycosylated protein with a molecular weight of 185 kDa. 
Amplification of c-erbB2 is a common feature in breast cancer. 
Overexpression is seen in 15-30 % of breast tumors and is associated with 
aggressive and invasive tumors and poor prognosis [16, 115]. Treatment with 
the monoclonal antibody trastuzumab (Herceptin) against c-erbB2 has a 
positive effect on overall survival and recurrence risk [116, 117]. Lapatinib, a 
tyrosine kinase inhibitor, is also used in treatment of c-erbB2 positive breast 
cancer [118]. Overexpression of the normal c-erbB2 protein, or point 
mutations in its transmembrane domain, has been shown to have a 
transforming effect on mammary epithelial cells. When overexpressed, c-
erbB2 can form active homodimers in the absence of ligand [119-121]. 
Association between c-erbB2 homodimerization and gene amplification has 
been shown in vivo, which also was associated with poor prognosis [122]. c-
erbB2 affects cell adhesion and migration, implicating a role for c-erbB2 in 
metastasis [123, 124]. Although the receptor commonly associated with EMT 
is the TGF-β receptor, there are studies also implicating c-erB2 in EMT. In 
an in vitro three-dimensional model system it was demonstrated that 
overexpressed c-erbB2 induces proliferation and disrupts tight junctions and 
epithelial polarity [125]. Overexpression of c-erbB2 in the mammary 
epithelial cell line MTSV1-7 inhibited transcription of E-cadherin [126]. In 
vivo selection of MCF-7 cells overexpressing c-erbB2 in nude mice, resulted 
in a sub-line that had underwent EMT [127].  
CTCs expressing EMT- and stem cell-associated markers have been detected 
in the blood of patients with c-erbB2 positive metastatic breast cancer [128]. 
As mentioned, EMT has been proposed to generate CSCs [81]. CSCs often 
Molecular factors influencing epithelial-mesenchymal transition in breast cancer 
10 
exhibit resistance to therapy [129]. It has been suggested that the mechanisms 
leading to resistance to the c-erbB2-targeting drugs trastuzumab and lapatinib 
in c-erbB2 positive breast cancer may be linked to induction of EMT [130, 
131]. 
In paper I, we have investigated the role of E-cadherin in c-erbB2-induced 
EMT. 
Nuclear factor I-C2 
Nuclear factor I-C2 (NFI-C2) is a member of the Nuclear factor I (NFI) 
transcription factor family. The NFI gene family consists of four members, 
NFI-A, NFI-B, NFI-C and NFI-X. NFI gene transcripts are differentially 
spliced [132] and expressed in unique but overlapping patterns [133-135]. 
The NFI proteins bind DNA as dimers at the consensus sequence 
TTGGC(N5)GCCAA and function as transcriptional activators as well as 
repressors of target genes [136]. NFI proteins are involved in regulation of 
genes controlled by e.g. insulin [137], TGF-β [138, 139], cAMP [137], 
steroid hormones [140], TNFα [141] and others. The unique expression 
patterns of NFI proteins suggests that they may play distinct roles in 
regulating tissue-specific gene expression during mammalian embryogenesis 
[134] and they have been demonstrated to be involved in cell differentiation 
[142, 143]. The oncogene Ras causes transformation of cells. It has been 
demonstrated that NFI can suppress Ras-induced transformation. 
Overexpression of NFI genes in chicken embryo inhibited transformation by 
subsequent overexpression of Ras in these cells [144]. Conversely, 
overexpression of Ras in mouse cells represses expression of NFI by 
affecting mRNA stability [145]. These studies suggest that loss of NFI 
function may promote tumor development. Furthermore, NFI proteins have 
been implicated in the function of the mammary gland after the identification 
of NFI binding sits in the genes for the milk proteins whey acidic protein 
(WAP) and carboxyl ester lipase (CEL) [146, 147]. 
Identification of specific NFI family members and isoforms involved in 
different processes has been hindered by the lack of specific antibodies. The 
responsible specific NFI protein is therefore unidentified in most studies. 
Our laboratory has demonstrated that the specific isoform NFI-C2 is the 
protein responsible for activation of the WAP and CEL promoters in the 
mouse mammary gland at mid-pregnancy [148]. Further studies suggest a 
broader role for NFI-C2 in the mouse mammary gland. Besides activation of 
milk genes, it was shown that NFI-C2 activates the tumor suppressor gene 
p53 at mid-pregnancy [149]. From these studies it was suggested that NFI-C2 
might participate both in the establishment of a functional gland and in the 
protection of the gland against tumorigenesis during proliferation. 
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The polypeptide hormone prolactin plays a critical role both in the 
differentiation of the gland during pregnancy and in the regulation of milk 
protein gene expression [150]. The prolactin receptor can activate a number 
of signaling pathways [151]. In mammary epithelial cells, prolactin binding 
to the prolactin receptor activates Jak2 (Janus tyrosine kinase 2). Activated 
Jak2 phosphorylates Stat5 (signal transducer and activator of transcription 5) 
that dimerizes and translocates to the nucleus where it binds and activates 
target genes [152]. The prolactin signaling pathway has also been 
demonstrated to play a role in maintenance of the NFI-C2 protein in 
mammary epithelial nuclei by regulating NFI-C2 protein levels. This occurs 
by a mechanism distinct from prolactin’s regulation of Stat5 [153]. Further 
studies demonstrated that prolactin via nuclear Jak2 regulates the amount of 
active NF1-C2 through tyrosine phosphorylation and protection against 
proteasomal degradation (Fig. 5) [154]. 
 
Figure 5. Proposed model of the prolactin-nuclear Jak2/NFI-C2 signaling pathway in 
mammary epithelial cells. Activation of Jak2 by prolactin/prolactin receptor (Prolactin-R) 
translocates Jak2 to the nucleus by an unknown mechanism. In the nucleus, Jak2 
phosphorylates NF1-C2 on tyrosine(s) and protects it from proteasomal degradation. The 
classical way by which prolactin transduces its signal in mammary gland is through the 
Jak2-Stat5 pathway. The figure is reprinted with permission from Nilsson et al [154]. 
The prolactin-nuclear Jak2/NFI-C2 signaling pathway was later implicated in 
the regulation of tumor development and EMT. It was shown that patients 
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with nuclear NFI-C2 in their breast cancer cells have better prognosis 
compared to those without detectable NFI-C2, and that NFI-C2 suppresses 
invasiveness and EMT by repressing the transcription factor Forkhead box F1 
(FoxF1) [155]. Paper II and paper III are continuations of that study, which 
will be discussed in more detail below. 
Forkhead box F1 
Forkhead box (Fox) proteins constitute a family of transcription factors that 
are related through the presence of a conserved forkhead or winged-helix 
DNA-binding domain. Fifty Fox genes have been identified in the human 
genome (FoxA to FoxS). Fox proteins bind DNA at the recognition core 
motif 5’ ((G/A)(T/C)(C/A)AA(C/T)A) 3’. Nucleotides outside this core motif 
are important for the specificity between the different Fox proteins [156]. 
Temporal and spatial restriction of expression patterns provides an additional 
level of specificity, as well as context dependence. For example, in the 
developing lung, FoxF1 and FoxF2 have overlapping but not identical 
expression patterns, suggesting that these transcription factors may have both 
similar and independent functions [157, 158]. 
FoxF1 acts as a transcriptional activator or repressor of target genes [157, 
159]. Early in development FoxF1 is required for differentiation of extra-
embryonic and lateral plate mesoderm and for mesodermal proliferation in 
the primitive streak. Inactivation of FoxF1 in mouse embryos is lethal and the 
embryos have abnormalities in the coelom, the amnion fails to expand and 
there is a lack of vasculogenesis [160]. Later in development, FoxF1 is 
expressed in the mesenchyme adjacent to the epithelium in the alimentary, 
respiratory and urinary tracts, where it is believed to regulate mesenchymal-
epithelial interactions [157]. In the developing lung, FoxF1 transcription is 
activated by Sonic hedgehog signaling [161, 162]. The effects of FoxF1 have 
been shown to be dependent on gene dosage [163]. FoxF1 heterozygous 
mouse pups show developmental defects in the gut, lungs, trachea, esophagus 
and gallbladder [161, 163-165]. In the adult, expression of FoxF1 is found in 
a range of tissues, e.g. in the gut, brain, eye and lung [166, 167]. In humans, 
the neonatal lethal disorder Alveolar capillary dysplasia with misalignment of 
pulmonary veins (ACDMPV) is linked to inactivating mutation of FoxF1 
[168].  
Fox proteins are important in a variety of biological processes, including 
metabolism, development, differentiation, proliferation, apoptosis and 
migration. As a consequence, loss or gain of Fox function can lead to 
tumorigenesis. Fox proteins have been suggested to act as either tumor 
suppressors or oncogenes [169].  
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The first study demonstrating a role of FoxF1 in tumorigenesis came from 
our laboratory. There, it was shown that in a mouse mammary epithelial cell 
line, FoxF1 overexpression induced EMT, migration and invasiveness. In 
addition, it was demonstrated that forced expression of FoxF1 enhanced 
xenograft tumorigenesis in nude mice [155]. FoxF1 has been shown to be 
important for mesenchymal cell migration by directly repressing integrin β3 
expression [159]. FoxF1 has also been shown to play a role in lung cancer 
associated fibroblasts, where FoxF1 expression stimulated cell migration and 
xenografted tumor growth [170]. In paper II, we have investigated the 
mechanisms responsible for FoxF1-enhanced invasion. 
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AIMS 
The objective of this thesis was to study the influence of different molecular 
factors on the EMT process associated with breast cancer cell invasion and 
metastasis and their possible use as biomarkers. 
The aim of paper I was to study the influence of oncogenic tyrosine kinase 
receptor signaling on EMT; specifically, to investigate the role of E-cadherin 
during c-erbB2-induced EMT, and in high cell-density dependent inhibition 
of EMT. 
In paper II, the objective was to study the role of NFI-C2 and FoxF1 in 
mammary carcinogenesis by identifying factors regulated by these 
transcription factors and involved in EMT and invasion and elucidate what 
mechanisms are responsible for FoxF1-enhanced invasion. 
Paper III aimed to investigate the prognostic value of NFI-C2 in breast 
cancer.  
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SPECIFIC BACKGROUND 
Paper I 
The human mammary epithelial cell line HB2 [171] is a subclone from the 
non-tumorigenic MTSV1-7 cell line. MTSV1-7 cells were obtained from 
luminal epithelial cells from milk and immortalized with the SV40 T antigen 
[172]. HB2 cells form spherical colonies in collagen and has been used for in 
vitro studies of branching morphogenesis [171]. Constitutive overexpression 
of c-erbB2 in MTSV1-7 cells causes irreversible changes in morphology and 
repression of E-cadherin [126, 173]. To study the order of events in c-erbB2-
signlaing effects, an inducible system in MTSV1-7 cells and HB2 cells was 
developed by Baeckström et al [174], using the hybrid receptor construct trk-
neu [175]. Trk-neu consists of the extracellular domain of the trkA nerve 
growth factor (NGF) receptor and the transmembrane and cytoplasmic 
domain of c-erbB2 (neu). c-erbB2 homodimerization and activation can be 
induced by NGF treatment of the cells (Fig. 6). 
 
Figure 6. The trk-neu hybrid receptor. The extracellular domain of trkA nerve 
growth factor (NGF) is fused to the transmembrane and cytoplasmic domains of c-
erbB2 (neu). NGF treatment induces homodimerization and tyrosine kinase (TK) 
activation and mimics c-erbB2 homodimerization. 
Induced c-erbB2 signaling inactivated integrin α2β1 leading to scattered 
growth in collagen. In addition, prolonged activation of c-erbB2 led to EMT 
[174]. Further studies using the high expressing clone HB2/tnz34 showed 
that c-erbB2-induced integrin inactivation was mediated by MEK/ERK 
signaling and PI3K dependent ILK and PKB signaling pathways [176]. 
Subsequent studies demonstrated that the EMT caused by prolonged 
induction of c-erbB2 signaling in HB2/tnz34 cells was irreversible and 
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associated with anchorage independent growth [177, 178]. Furthermore, c-
erbB2-induced EMT was suppressed when cells were grown at high density. 
It was hypothesized that E-cadherin homophilic interaction can suppress 
EMT. It was also observed that the initial cell-scattering associated with 
EMT occurred before downregulation of E-cadherin [177]. 
In paper I, we aimed to analyze a possible role for E-cadherin in cell-cell 
contact-inhibition of c-erbB2-induced EMT. 
Paper II 
In paper II we used three different cell lines; HC11, MDA-MB-436 and HB2.  
HC11 cells are a mouse epithelial cell line cloned from the COMMA-1D cell 
line, which is derived from mammary tissue of BALB/c mice at mid-
pregnancy [179, 180]. HC11 cells have been used for in vitro studies of 
epithelial cell proliferation, signal transduction and differentiation. MDA-
MB-436 is a mesenchymal human breast carcinoma cell line derived from 
metastatic site (pleural effusion) and have been used for studying triple-
negative breast cancer [181]. HB2 cells are described in the previous section. 
As mentioned, in a previous paper it was demonstrated that the 
prolactin/nuclear Jak2/NFI-C2-pathway plays a role in breast cancer by 
regulating EMT, motility and invasion [154]. In order to study the effects of 
NFI-C2 without the involvement of other effectors stimulated by prolactin, a 
stable form of NFI-C2 (NFI-C2S) was stably transfected in HC11 cells. A 
point mutation protects NFI-C2S from proteasomal degradation in the 
absence of nuclear Jak2. NFI-C2S expression in HC11 cells increased 
epithelial characteristics and impeded migration. NFI-C2S expression in 
mesenchymal MDA-MB-436 cells lead to loss of some mesenchymal 
characteristics, decreased in vitro invasion and abolished xenografted tumor 
growth in nude mice, suggesting that NFI-C2 is a suppressor of tumor 
progression and EMT. This was underscored by the observation that NFI-C2 
status of primary breast cancer correlated with survival and its expression 
was lost in lymph node metastases (discussed in the next section, paper III). 
Affymetrix microarray analysis of the transcriptome of MDA-MB-436 cells 
expressing NFI-C2S or control vector identified the FoxF1 gene to be one of 
the most downregulated by NFI-C2, and it was also shown that FoxF1 is a 
direct target of NFI-C2. FoxF1 overexpression in HC11 cells induced EMT, 
increased in vitro invasion capacity and enhanced xenografted tumorigenesis 
in nude mice. 
In paper II, we wanted to further study the roles NFI-C2 and FoxF1 in EMT 
and invasion, primarily by identifying targets that are oppositely regulated by 
these factors and involved in EMT and invasion. 
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Paper III 
Prognostic markers are used in the evaluation of a cancer patient’s risk of 
relapse and disease progression. Prognostic markers include tumor size, 
axillary lymph node status, histologic grade, patient age and menopausal 
status. In addition, molecular markers are used to further help to predict 
prognosis or treatment response, e.g. Ki67, estrogen receptor (ER), 
progesterone receptor (PR) and HER2. However, these factors are unable to 
accurate predict which tumor will recur and to indicate responses to different 
therapies and therefore there is a need to find new prognostic markers. 
It has previously been demonstrated that the presence of NFI-C2 in breast 
tumors has a clinical relevance [155]. The status of NFI-C2 was analyzed by 
immunohistochemistry in a tissue microarray containing 292 samples from 
patients diagnosed with stage II invasive breast cancer. Tumor cells had a 
weaker staining of NFI-C2 compared to normal glandular cells and only 1 of 
159 lymph node metastases stained positive for NFI-C2. Patients with NFI-
C2 in their tumor cells (74 of 292) had better prognosis compared to those 
without detectable NFI-C2, suggesting that NFI-C2 is a tumor suppressor. 
Furthermore, there was a correlation of nuclear Jak2 and NFI-C2 in tumor 
biopsies, indicating that the regulation of the nuclear levels of NFI-C2 by the 
prolactin/Jak2/NFI-C2 pathway also occurs in cancer. 
These findings, together with the finding that NFI-C2 suppresses EMT, make 
NFI-C2 a candidate as a prognostic marker. In paper III, we aimed to 
investigate the prognostic value of NFI-C2 in a mixed cohort of breast cancer 
patients. We also analyzed the levels of NFI-C2 protein after tamoxifen 
treatment in cellular extracts from T47D and 4T1 cells. T47D is a human 
breast cancer cell line derived from metastatic site (pleural effusion). This 
cell line has epithelial morphology and is non-invasive. 4T1 is a mouse 
mammary tumor cell line with epithelial morphology. 4T1 cells form highly 
metastatic tumors when injected to BALB/c mice and are frequently used as a 
model for metastatic breast cancer. This is also a luciferase based model and 
the metastatic process can be followed by using bioluminescence in live 
animals. 
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RESULTS AND DISCUSSION 
Loss of E-cadherin expression is not a prerequisite 
for c-erbB2-induced epithelial-mesenchymal 
transition (paper I). 
In paper I, we have further investigated earlier observations that cells 
undergoing the first scattering phase in c-erbB2 induced EMT still expressed 
surface-bound E-cadherin, and that the progression of EMT was delayed by 
cell-cell contact [177]. These observations raised the questions whether loss 
of E-cadherin expression is a cause or a consequence of EMT and if cell 
density-dependent suppression of EMT is mediated by E-cadherin binding 
between cells. 
In order to analyze a possible modulation of c-erbB2-induced EMT by E-
cadherin, an inducible system for ectopic expression of E-cadherin in cells 
stably expressing the trk/neu hybrid receptor (HB2/tnz34) was created. This 
generated the clones TrE-ep1 and TrE-ep5 (ep for epithelial morphology). 
TrE-ep5 cells were grown at low density with a combination of c-erbB2 
signaling and ectopic E-cadherin expression. By subsequently analyzing 
changes in expression and localization of epithelial- and mesenchymal 
markers, using flow cytometry and immunofluorescence, we could show that 
the forced expression of E-cadherin did not prevent the progression of EMT, 
as compared to cells with c-erbB2 signaling only. EMT requires loss of cell-
cell adhesion and since E-cadherin is a major component in cell-cell contacts, 
loss of its expression is considered to be a fundamental event. However, it 
has been observed also in other model systems that EMT can occur without 
simultaneous downregulation of E-cadherin. For example, EGF-induced 
EMT in MDA-MB-468 cells occurred without complete downregulation of 
E-cadherin [182, 183]. In the present study, we showed that cell scattering 
following overnight EGF treatment of MDA-MB-468 cells occurred without 
major changes in surface-bound E-cadherin, implicating that downregulation 
of E-cadherin is not essential in at least the early phase of EMT. 
In a fibroblastic clone (TrE-fib), isolated after prolonged c-erbB2 signaling in 
the presence of E-cadherin, the endogenous CDH1 gene had been silenced. 
Induced expression of ectopic E-cadherin did not have any effect on 
morphology in these cells, suggesting that E-cadherin had lost its function. 
Performing dissociation assays on confluent TrE-ep5 and TrE-fib cells 
showed that induced expression of E-cadherin increased cell-cell adhesion in 
TrE-ep5 cells. In contrast, in fibroblastic TrE-fib cells, E-cadherin did not 
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have a restoring effect on cell-cell adhesion. These results further supported 
our assumption that the function of E-cadherin is lost in fibroblastic cells. In 
addition, the attachment of E-cadherin to the cytoskeleton was weaker in 
fibroblastic cells and β-catenin and α-catenin were localized to the cytoplasm 
and nucleus, although the localization of E-cadherin was grossly the same in 
epithelial and fibroblastic cells. It has previously been shown that c-erbB2 
signaling in HB2 cells results in destabilization of the cortical cytoskeleton 
[184]. Rearrangements of the cytoskeleton may lead to difficulties in 
supporting E-cadherin mediated cell-cell adhesion, allowing cells to separate 
even in the presence of surface-bound E-cadherin.  
The observation that the progression of c-erbB2-induced EMT was delayed 
by cell-cell contact raised the question whether cell-cell contact results in 
intracellular signaling events that hinder the EMT process. If such cell-cell 
contact-dependent signaling events are mediated by E-cadherin, then 
interfering with E-cadherin function would allow cells grown at high density 
to undergo c-erbB2-induced EMT. To test this hypothesis, we expressed a 
mutant E-cadherin, where the adhesive function is abolished [90]. Cells 
expressing this mutant construct, TrE
wv
-ep, showed a decrease in cell-cell 
adhesion. However, the combination of c-erbB2 signaling and mutant E-
cadherin expression in high density cultures did not result in progression of 
EMT. This indicates that E-cadherin is not involved in mediation of density-
dependent inhibition of c-erbB2-induced EMT.  
It has been demonstrated that MMP3 and Rac1b, factors that stimulate 
alterations in the cytoskeleton, induce EMT in mammary epithelial cells. This 
MMP3/Rac1b-induced EMT was dependent on the cells ability to spread 
over a larger surface. When the available surface area was limited 
MMP3/Rac1b-induced EMT was blocked [185], suggesting cell shape as an 
important factor in the initiation of EMT. 
Our findings suggest that loss of E-cadherin expression may be a 
consequence rather than a cause of c-erbB2-induced EMT, and further that 
density-dependent inhibition of c-erbB2-induced EMT is not mediated by E-
cadherin. We propose that cytoskeletal rearrangements in the initial phase of 
EMT may be the mechanism leading to cell-cell separation by impairment of 
E-cadherin function and cell-cell adhesion. These rearrangements might also 
be important in density-dependent inhibition of EMT by eliciting signals, in 
crowded cells, that control EMT progression. 
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Forkhead Box F1 promotes breast cancer cell 
migration by upregulating lysyl oxidase and 
suppressing Smad2/3 signaling (paper II). 
The aim of this study was to further investigate the roles of NFI-C2 and 
FoxF1 in EMT and invasion. Using Affymetrix microarray analysis, we 
could compare the transcriptome of HC11 wild type cells to that of cells 
overexpressing NFI-C2S or FoxF1 and find targets that are oppositely 
regulated by these factors, involved in EMT and invasion. In order to identify 
factors that might be generally important in EMT and regulated by NFI-C2, 
we used the data from a previous array where the transcriptome of MDA-
MB-436 cells was compared to that of MDA-MB-436 cells overexpressing 
NFI-C2S [155]. 45 genes were downregulated 1.5 fold or more by NFI-C2 in 
both these cell lines. Of these 45 genes, 17 were upregulated 1.5 fold or more 
by FoxF1 overexpression in HC11 cells. The gene that was by far most 
upregulated by FoxF1 was lysyl oxidase (LOX). LOX is an ECM enzyme that 
catalyzes the cross-linking of collagens or elastin, thereby controlling the 
structure and tensile strength of the ECM, but is also implicated in EMT and 
tumor progression to metastasis [186-189]. LOX has been demonstrated to be 
upregulated in invasive breast cancer cell lines and breast carcinomas [190, 
191]. LOX was therefore a potential factor involved in the enhanced in vitro 
invasion capacity observed following FoxF1 overexpression in HC11 cells. 
We could detect high levels of secreted LOX in culture media from 
HC11FoxF1 cells. In addition, we could show that the enhanced in vitro 
invasion capacity of HC11FoxF1 cells was mediated by LOX, as treatment 
with a LOX inhibitor or reduction of LOX expression using RNAi, 
significantly decreased the capacity of HC11FoxF1 cells to migrate through 
matrigel. Taken together, we found LOX to be downregulated by NFI-C2 and 
upregulated by FoxF1 and responsible for the increased invasion capacity of 
HC11FoxF1 cells. These findings together with the previous observations 
that FoxF1 is repressed by NFI-C2 which expression is lost during tumor 
progression, suggests that loss of NFI-C2 may lead to expression of factors 
like FoxF1 and LOX leading to EMT and carcinoma cell dissemination. 
Several of the 17 genes that were shown to be downregulated by NFI-C2 and 
upregulated by FoxF1 are known to be involved in TGF-β signaling and 
TGF-β associated EMT. In addition, LOX has been shown to be involved in 
TGF-β induced EMT [192]. This raised the question whether FoxF1 is 
involved in the regulation of TGF-β signaling pathways.  
TGF-β is important for mammary gland development and function and in the 
suppression of tumorigenesis. Breast cancer progression can convert the 
function of TGF-β to become a tumor promoting factor [193, 194]. The 
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oncogenic activity of TGF-β is suggested to be a result from imbalance 
between canonical (Smad2/3) and non-canonical (non-Smad) TGF-β 
signaling systems, where the non-canonical pathways are believed to promote 
EMT and invasive and metastatic properties of cancer cells. The non-Smad 
pathways include various branches of MAP kinase pathways, e.g. p38 MAPK 
[195].  
We investigated whether TGF-β signaling pathways are affected by FoxF1 
and found that the Smad2/3 pathway is suppressed while the p38 MAPK 
signaling pathway is activated in HC11FoxF1 cells. 
LOX has been demonstrated to control the activity of focal adhesion kinase 
(FAK) [32, 186, 189, 196]. We found that FoxF1 activates FAK in a LOX-
dependent manner, as depletion of LOX by RNAi decreased the activity of 
FAK. In addition, LOX depletion activated the Smad2/3 signaling pathway 
by increasing the levels of Smad2/3 and the phosphorylation of Smad2. 
However, FAK inhibitor treatment showed that FAK is involved in the 
activation of Smad2 but not in the regulation of total Smad2/3 levels, 
suggesting that downstream of LOX there are additional factors involved in 
the regulation of Smad2/3 levels. The main findings are summarized in figure 
7. 
 
Figure 7. Schematic picture of signaling pathways regulated by FoxF1. 
In this study we found LOX, which is upregulated in breast carcinomas and 
shown to promote metastasis, to be highly expressed in response to FoxF1 
overexpression. In addition, FoxF1-induced invasiveness was shown to be 
dependent on LOX activity, suggesting that induction of EMT and 
invasiveness by FoxF1 may have an important role during breast tumor 
progression to metastasis. Furthermore, we found FoxF1 to be involved in 
TGF-β signaling pathways known to be important during breast cancer 
progression. However, the possible connection between FoxF1 and TGF-β 
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and whether these factors cooperate to influence metastatic activity needs to 
be further investigated. 
Nuclear factor I-C2 is a powerful prognostic marker 
in breast cancer (paper III). 
In this study, a tissue microarray was constructed from the tissue samples of 
498 patients with primary invasive breast cancer diagnosed at the Malmö 
University Hospital, Malmö, Sweden, between 1988 and 1992 [197]. Of 
these 498 patients the expression level of NFI-C2 could be analyzed in 462 
cases, using immunohistochemistry. 217 patients stained positive and 245 
stained negative for NFI-C2. The expression of NFI-C2 was positively 
associated with advanced age, ERα expression and PR expression, and 
negatively associated with HER2 overexpression, lymph node status, tumor 
size, Ki67 expression and histological grade. This shows that NFI-C2 is 
positively associated with markers for good prognosis, suggesting that tumors 
with NFI-C2 expression may be less aggressive than tumors without NFI-C2 
expression. 
Kaplan-Meier analysis of all patients showed a significantly lower risk for 
recurrence and mortality from breast cancer for NFI-C2 positive compared to 
NFI-C2 negative patients, demonstrating an association between NFI-C2 and 
good prognosis. However, this association was only significant for patients 
with ERα-positive tumors. 
Kaplan-Meier analysis of the patients that had not received any adjuvant 
treatment showed that NFI-C2 was associated with increased recurrence-free 
survival (RFS) and breast cancer-specific survival (BCSS), demonstrating a 
prognostic value of NFI-C2. Multivariate Cox analysis including age, tumor 
size, ERα, PR, Ki67, HER2, and lymph node status demonstrated that NFI-
C2 was an independent predictor of RFS. NFI-C2 remained an independent 
predictor of RFS in the ERα-positive group, indicating that NFI-C2 has an 
additional value in predicting breast cancer recurrence besides that of the ER 
status.  
NFI-C2 suppresses EMT and its expression is lost during breast cancer 
progression [155], suggesting that loss of NFI-C2 may facilitate the 
dissemination of carcinoma cells from the primary tumor and thereby the 
generation of CTCs. It has been demonstrated that the presence of CTCs 
correlates with lymph node metastases [198]. We therefore investigated the 
association between NFI-C2, lymph node status and RFS in the group of 
patients that had received tamoxifen treatment. The group of untreated 
patients could not be analyzed due to the low number with multiple lymph 
node metastases. We found that NFI-C2 was positively associated to RFS in 
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patients with no lymph node metastases whereas in patients with multiple 
lymph node metastases, NFI-C2 was negatively associated to RFS. 
Furthermore, lymph node status was only prognostic in the group of patients 
with NFI-C2 positive tumors. These data suggest that the role of NFI-C2 
changes during breast cancer progression. 
We investigated whether tamoxifen had an effect on NFI-C2 protein levels in 
two different breast cancer cell lines and found that tamoxifen reduced the 
levels of NFI-C2 in 4T1 cells, known to form metastases, while it had no 
effect on NFI-C2 levels in the non-invasive T47D cell line. Removing 
tamoxifen from 4T1 cells restored the levels of NFI-C2.  
This study supports our hypothesis that NFI-C2 is a tumor suppressor and 
shows that NFI-C2 is a prognostic factor associated with good prognosis in 
breast cancer. However, it also provides data suggesting that the presence of 
NFI-C2 may in some instances instead be negative. NFI-C2 protein levels 
were differently affected by tamoxifen which might be dependent on the 
cellular phenotype. NFI-C2 has been shown to promote MET [155], which is 
believed to be a critical process in metastasis formation (described in the 
introduction). In patients with no lymph node metastases the presence of 
NFI-C2 would have a positive effect inhibiting EMT to occur. However, in 
patients with many lymph node metastases and presumably also harboring 
CTCs in their blood and lymphatic system, the presence of NFI-C2 in these 
circulating cancer cells might lead to MET and an increased risk for 
colonization and metastases formation. Our results indicate that during 
tamoxifen treatment the NFI-C2 levels are low whereas they increase when 
treatment is ended. If patients who have ended a tamoxifen treatment still has 
CTCs and the levels of NFI-C2 would increase, this might lead to a higher 
risk for metastases formation.  
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FUTURE ASPECTS 
The subject of this thesis was to investigate how different molecular factors 
influence EMT. This thesis shows that c-erb2-induced EMT can proceed in 
the presence of the adhesion molecule E-cadherin and that cell density-
dependent inhibition of EMT is not mediated by E-cadherin. Furthermore, it 
demonstrates an involvement of NFI-C2 and FoxF1 in the regulation of 
molecular factors and signaling pathways that are associated to EMT and 
invasion. We identified a signaling pathway where FoxF1 upregulated LOX 
in a FAK-dependent manner leading to suppression of Smad2/3 and 
increased invasion. In addition, NFI-C2 was confirmed to be a prognostic 
marker associated with good prognosis in breast cancer. In future work there 
are several aspects that can be further investigated.  
The occurrence of a mechanism that can hinder EMT is intriguing. If EMT 
events are the cause of carcinoma cell dissemination and invasion, 
understanding such a mechanism would give critical insights into the process 
of metastases and possibly identify potential therapy targets. The effects of 
cytoskeletal rearrangements and cell shape seem to be important for the EMT 
process to occur and would be interesting to investigate further. Identifying 
factors that induce cytoskeletal rearrangements and cell spreading (including 
cell-surface targets other than E-cadherin) during EMT initiation would give 
information about a possible association between cell morphology and 
carcinoma progression. 
To get further insight into the role of FoxF1 during carcinogenesis it would 
be of importance to evaluate the effects of FoxF1 in vivo. In an ongoing 
study, a transgenic mouse model for mammary carcinogenesis is used where 
c-myc is specifically overexpressed in the mammary epithelium under control 
of the WAP-promoter, causing tumor development after pregnancy [199]. In 
this model, FoxF1 is specifically knocked-out in the epithelium by utilizing 
the cre/lox system where cre is expressed under the control of the promoter of 
keratin 14. This model system will give insights into the effects of FoxF1-
removal on tumor development and progression. 
In addition, the 4T1 cell line can be used to study FoxF1 effect on metastatic 
capability. We hypothesize that implantation of 4T1 cells overexpressing 
FoxF1 into the fat pads of BALB/c mice may result in less formation of 
metastases compared to control. FoxF1 overexpression would possibly result 
in cancer cells with mesenchymal properties which would impede the ability 
to colonize and form metastases. 
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The role of NFI-C2 as a prognostic marker was evaluated in a 
nonrandomized trial. In order to evaluate the treatment predictive value of 
NFI-C2, a randomized trial needs to be used containing a large number of 
patients that has or has not received treatment. 
To approach the question whether the level of NFI-C2 protein affects the 
tumor cells' capacity to metastasize, the 4T1 cell line can be utilized. 4T1 
cells where NFI-C2 has been knocked-down and control cells can be 
implanted into the fat pads of BALB/c mice and their metastatic capability 
compared. If NFI-C2 promotes MET then the NFI-C2 knock-down cells will 
be more mesenchymal, and as a consequence of that, less capable to colonize 
and form metastases.  
To elucidate the dual effects of NFI-C2 positivity depending on tumor 
progression stage, one can overexpress NF1-C2 in 4T1 cells. Implantation of 
these cells in the mammary fat pads of BALB/c mice might give rise to 
tumors with less metastatic capability compared to control. On the other 
hand, if NFI-C2 overexpressing cells instead were injected into the tail, 
resulting in cells entering the bloodstream, this might instead increase the 
metastatic capability. We hypothesize that NFI-C2 overexpression would 
generate cancer cells with epithelial properties enabling attachment at distant 
sites and metastasis formation. 
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